Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis

Authors

  • Roselie E. Achten Department of Dermatology and Allergology, University Medical Center Utrecht, Heidelberglaan 100, NL-3584 CX Utrecht, the Netherlands
  • Chantal M. van Luijk
  • Lisa P. van der Rijst
  • Daphne S. Bakker
  • Lotte S. Spekhorst
  • Nicolaas P. A. Zuithoff
  • Marie L. A. Schuttelaar
  • Geertruida L. E. Romeijn
  • Angelique N. Voorberg
  • Marijke Kamsteeg
  • Inge M. Haeck
  • Marlies de Graaf
  • Judith L. Thijs
  • Joke H. de Boer
  • Marjolein S. de Bruin-Weller

DOI:

https://doi.org/10.2340/actadv.v102.1128

Keywords:

conjunctivitis, dupilumab, dupilumab-associated ocular surface disease, DAOSD

Abstract

This study identified risk factors for the development of dupilumab-associated ocular surface disease in patients with moderate-to-severe atopic dermatitis in a large prospective daily practice cohort. Data from the Dutch BioDay Registry were used to assess the risk of developing dupilumab-associated ocular surface disease, by performing univariate and multivariate logistic regression analyses. A total of 469 patients were included, of which 152/469 (32.4%) developed dupilumab-associated ocular surface disease. Multivariate analysis showed a statistically significant association of the development of dupilumab-associated ocular surface disease with a history of any eye disease (history of self-reported episodic acute allergic conjunctivitis excluded) combined with the use of ophthalmic medication at the start of dupilumab (odds ratio 5.16, 95% confidence interval 2.30–11.56, p < 0.001). In conclusion, a history of any eye disease (history of self-reported episodic acute allergic conjunctivitis excluded) combined with the use of ophthalmic medication at baseline was associated with the development of dupilumab-associated ocular surface disease in patients with atopic dermatitis.

Downloads

Download data is not yet available.

References

de Bruin-Weller M, Thaci D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol 2018; 178: 1083-1101.

https://doi.org/10.1111/bjd.16156

Faiz S, Giovannelli J, Podevin C, Jachiet M, Bouaziz JD, Reguiai Z, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol 2019; 81: 143-151.

https://doi.org/10.1016/j.jaad.2019.02.053

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2287-2303.

https://doi.org/10.1016/S0140-6736(17)31191-1

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335-2348.

https://doi.org/10.1056/NEJMoa1610020

Ariens LF, van der Schaft J, Spekhorst LS, Bakker DS, Romeijn GLE, Kouwenhoven TA, et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry. J Am Acad Dermatol 2021; 84: 1000-1009.

https://doi.org/10.1016/j.jaad.2020.08.127

Olesen CM, Holm JG, Norreslet LB, Serup JV, Thomsen SF, Agner T. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre. J Eur Acad Dermatol Venereol 2019; 33: 1562-1568.

https://doi.org/10.1111/jdv.15609

Popiela MZ, Barbara R, Turnbull AMJ, Corden E, Martinez-Falero BS, O'Driscoll D, et al. Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae. Eye (Lond) 2021; 35: 3277-3284.

https://doi.org/10.1038/s41433-020-01379-9

Bohner A, Topham C, Strunck J, Haynes D, Brazil M, Clements J, et al. Dupilumab-associated ocular surface disease: clinical characteristics, treatment, and follow-up. Cornea 2021; 40: 584-589.

https://doi.org/10.1097/ICO.0000000000002461

Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol 2019; 181: 459-473.

https://doi.org/10.1111/bjd.17869

Ariens LFM, van der Schaft J, Bakker DS, Balak D, Romeijn MLE, Kouwenhoven T, et al. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry. Allergy 2020; 75: 116-126.

https://doi.org/10.1111/all.14080

Treister AD, Kraff-Cooper C, Lio PA. Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol 2018; 154: 1208-1211.

https://doi.org/10.1001/jamadermatol.2018.2690

Uchida H, Kamata M, Nagata M, Fukaya S, Hayashi K, Fukuyasu A, et al. Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting. J Am Acad Dermatol 2020; 82: 1247-1249.

https://doi.org/10.1016/j.jaad.2019.12.039

Nettis E, Bonzano L, Patella V, Detoraki A, Trerotoli P, Lombardo C, et al. Dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience. J Investig Allergol Clin Immunol 2020; 30: 201-204.

https://doi.org/10.18176/jiaci.0481

Touhouche AT, Cassagne M, Berard E, Giordano-Labadie F, Didier A, Fournie P, et al. Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study. J Eur Acad Dermatol Venereol 2021; 35: 172-179.

https://doi.org/10.1111/jdv.16724

Achten R, Bakker D, Ariens L, Lans A, Thijs J, van der Schaft J, et al. Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract 2021; 9: 1389-1392.e2.

https://doi.org/10.1016/j.jaip.2020.09.042

Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol 2017; 177: 1316-1321.

https://doi.org/10.1111/bjd.15641

Thyssen JP. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels? Br J Dermatol 2018; 178: 1220.

https://doi.org/10.1111/bjd.16330

Thyssen JP, Toft PB, Halling-Overgaard AS, Gislason GH, Skov L, Egeberg A. Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. J Am Acad Dermatol 2017; 77: 280-286.e1.

https://doi.org/10.1016/j.jaad.2017.03.003

Simonetti O, Radi G, Diotallevi F, Molinelli E, Rizzetto G, Offidani A. Prevention of conjunctivitis in patients with atopic dermatitis undergoing treatment with dupilumab: an Italian single centre experience. Clin Exp Dermatol 2021; 46: 939-940.

https://doi.org/10.1111/ced.14611

Harrell Jr FE. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis: Springer; 2015.

https://doi.org/10.1007/978-3-319-19425-7

Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Strat Soc 1995; 57: 289-300.

https://doi.org/10.1111/j.2517-6161.1995.tb02031.x

Hong J, Bielory L. Allergy to ophthalmic preservatives. Curr Opin Allergy Clin Immunol 2009; 9: 447-453.

https://doi.org/10.1097/ACI.0b013e3283306990

Beck KM, Seitzman GD, Yang EJ, Sanchez IM, Liao W. Ocular co-morbidities of atopic dermatitis. Part I: associated ocular diseases. Am J Clin Dermatol 2019; 20: 797-805.

https://doi.org/10.1007/s40257-019-00455-5

Beck KM, Seitzman GD, Yang EJ, Sanchez IM, Liao W. Ocular co-morbidities of atopic dermatitis. Part II: ocular disease secondary to treatments. Am J Clin Dermatol 2019; 20: 807-815.

https://doi.org/10.1007/s40257-019-00465-3

Dogru M, Nakagawa N, Tetsumoto K, Katakami C, Yamamoto M. Ocular surface disease in atopic dermatitis. Jpn J Ophthalmol 1999; 43: 53-57.

https://doi.org/10.1016/S0021-5155(98)00061-6

Dogru M, Katakami C, Nakagawa N, Tetsumoto K, Yamamoto M. Impression cytology in atopic dermatitis. Ophthalmology 1998; 105: 1478-1484.

https://doi.org/10.1016/S0161-6420(98)98032-0

Downloads

Additional Files

Published

2022-03-10

How to Cite

Achten, R. E., van Luijk, C., van der Rijst, L. ., Bakker, D., Spekhorst, L., Zuithoff, N., Schuttelaar, M., Romeijn, G., Voorberg, A., Kamsteeg, M. ., Haeck, I., de Graaf, M. ., Thijs, J. ., de Boer, J. ., & de Bruin-Weller, M. (2022). Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis. Acta Dermato-Venereologica, 102, adv00666. https://doi.org/10.2340/actadv.v102.1128

Issue

Section

Articles

Categories